Drug

HutchMed's Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC
CancerCombination therapy

HutchMed’s Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced that regulatory applications for the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) have been accepted for review in Europe and Japan.…

InventisBio's Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

InventisBio’s Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

Nuance Pharma Doses First Participant in REACH Phase III Trial of STG320 for House Dust Mite Allergic Rhinitis in China

Nuance Pharma Doses First Participant in REACH Phase III Trial of STG320 for House Dust Mite Allergic Rhinitis in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AstraZenecaClinical trial results

AstraZeneca’s Tozorakimab Reduces COPD Exacerbations in Phase III Trials, Targeting IL-33 in First-in-Class Approach

J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety
Auto-immuneClinical trial results

J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety

Auto-immuneClinical trial results

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity

Eli Lilly’s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial
Auto-immuneClinical trial results

Eli Lilly’s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial

Show More